An a day workshop for medical scientists and healthcare professionals to plans for the future to discuss research is for asbestos the Wellcome Trust, London on 23 November 2010 take place. Latest research on the causes and the development of asbestos-related diseases such as asbestosis and mesothelioma, will be presented together with the possible connections between carbon nano-particles and occupational lung disease.
According to British Lung Foundation better treatments for patients with asbestos-related diseases still needs the palliative services currently available for the discharge of Mesothelioma Cancer sufferer found an increase in quality research required.
One of the conditions that are covered in the workshop is the deadly Mesothelioma Cancer, which is almost exclusively caused by asbestos exposure, and for that there is currently no cure. Even since the final prohibition of white asbestos as late as the 1980s/1990s years inhalation of deadly asbestos in the workplace has led claim over 200,000 lives to more than 2,000 deaths per year, with mesothelioma alone.
Still one of Britain's largest industrial killers is asbestos-related diseases and mesothelioma claims for damages are expected to continue at least 2050.
After a symptoms that average mesothelioma is life expectancy for patients between 4 and 18 months after the diagnosis and treatment options provide only temporary relief of symptoms long wait between 15-50 years before the first exposure and final beginning of asbestosis.
However, Congress were presented at the 35th European society for medical oncology (ESMO), recently in Milan, research, proposed by both the Tomudex and vitamin E in the fight against Mesothelioma Cancer can be useful. A form of vitamin D in the body has been shown to be effective in the treatment of breast cancer tumours and possibly inducing cell death and suppressing malignant mesothelioma cancer growth successful.
Tomudex fight cancer by preventing cancer cell growth, eventually leads to their elimination. Tomudex is currently available for the treatment of malignant pleural mesothelioma in Portugal Czech Republic and Hungary licensed and is expected to be used in other European countries until end of 2010 are allowed.
